1. Search Result
Search Result
Results for "

Solid

" in MedChemExpress (MCE) Product Catalog:

740

Inhibitors & Agonists

2

Screening Libraries

36

Fluorescent Dye

43

Biochemical Assay Reagents

50

Peptides

171

Inhibitory Antibodies

39

Natural
Products

20

Isotope-Labeled Compounds

5

Click Chemistry

17

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125924
    DSPE-PEG-Amine, MW 2000 ammonium
    1 Publications Verification

    DSPE-PEG-NH2, MW 2000 ammonium; DSPE-PEG(2000) Amine ammonium

    Liposome Others
    DSPE-PEG-Amine, MW 2000 (ammonium), an amine derivative of phospholipid poly ethylene glycol, is used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents .
    DSPE-PEG-Amine, MW 2000 ammonium
  • HY-101266
    Milademetan
    5 Publications Verification

    DS-3032

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis .
    Milademetan
  • HY-137435
    Cirtuvivint
    2 Publications Verification

    SM08502

    CDK Cancer
    Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research .
    Cirtuvivint
  • HY-P99100
    Visugromab
    2 Publications Verification

    CTL-002

    TGF-beta/Smad PD-1/PD-L1 Cancer
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Visugromab
  • HY-137457
    Venadaparib
    1 Publications Verification

    IDX-1197

    PARP Cancer
    Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib does not sensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research .
    Venadaparib
  • HY-172320

    PD-1/PD-L1 Cancer
    BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .
    BMS-986238
  • HY-P99489

    ABBV 181; PR 1648817

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
    Budigalimab
  • HY-P99708

    ABBV-151; ARGX-115

    TGF-beta/Smad Cancer
    Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
    Livmoniplimab
  • HY-P99271

    Anti-Human F3 Recombinant Antibody

    ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P3448

    CEND-1; iRGD; LSTA1

    Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
    Certepetide
  • HY-128587
    Mevociclib
    5+ Cited Publications

    SY-1365

    CDK Cancer
    Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .
    Mevociclib
  • HY-P99450

    IPH 5401; Anti-C5aR1 mAb

    Complement System Inflammation/Immunology Cancer
    Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
    Avdoralimab
  • HY-128995A

    Glycyl-DX-8951 TFA; Exatecan analog 2 TFA

    Drug Derivative Cancer
    Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research .
    Glycyl-Exatecan TFA
  • HY-172663A

    DNA/RNA Synthesis Apoptosis Cancer
    Trabectedin derivative 1 TFA is a selective DNA minor groove binder. Trabectedin derivative 1 TFA inhibits DNA transcription and repair to induce tumor cell apoptosis. Trabectedin derivative 1 TFA is promising for research of solid tumors such as soft tissue sarcoma and ovarian cancer .
    Trabectedin derivative 1 TFA
  • HY-P99827

    TSR-022; GSK4069889

    Tim3 Cancer
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
    Cobolimab
  • HY-P991451

    SGN-ALPV antibody

    Phosphatase Cancer
    Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research .
    Anti-ALPP Antibody
  • HY-P991396

    Tim3 Cancer
    LY-3321367 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. LY-3321367 can be used in solid tumors research .
    LY-3321367
  • HY-P991449

    PD-1/PD-L1 Tim3 Cancer
    LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .
    LY3415244
  • HY-W012184

    Biochemical Assay Reagents Inflammation/Immunology
    CDAP is an organic cyanylating reagent that can be used for preparation of solid phase affinity reagents, modification of protein thiols and nucleotide delivery. CDAP also activates polysaccharides with a variety of chemical properties. CDAP can be used to prepare conjugate vaccines and other immune reagents .
    CDAP
  • HY-23408

    PROTAC Linkers Cancer
    Tos-PEG3 is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Tos-PEG3 (structure 1) can be used for the synthesis of 3'-aminooxy oligonucleotides solid supports .
    Tos-PEG3
  • HY-135737
    Dicaprylyl carbonate
    1 Publications Verification

    Dioctyl carbonate

    Others Others
    Dicaprylyl carbonate, a solid, plant-derived fat, is a dry emollient. Dicaprylyl carbonate has excellent dermatological compatibility and a comprehensive performance profile, such as solubilizing and dispersing ability for sun-care filters .
    Dicaprylyl carbonate
  • HY-P99475

    MSB-2311

    PD-1/PD-L1 Cancer
    Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
    Betifisolimab
  • HY-P991193

    TNF Receptor Cancer
    NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
    NGM-438
  • HY-101266B
    Milademetan tosylate hydrate
    5 Publications Verification

    DS-3032b; DS-3032 tosylate hydrate

    MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .
    Milademetan tosylate hydrate
  • HY-177083

    AVA-6000

    FAP Cancer
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .
    Faridoxorubicin
  • HY-P991402

    TNF Receptor Cancer
    BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
    BI-1910
  • HY-162006

    Pim Apoptosis Autophagy Metabolic Disease Inflammation/Immunology Cancer
    Pim-1 kinase inhibitor 8 is a potent PIM-1 inhibitor with an IC50 value of 14.3 nM. Pim-1 kinase inhibitor 8 impedes cell proliferation and migration through PIM-1 inhibition and the induction of both apoptosis and autophagy. Pim-1 kinase inhibitor 8 inhibits solid tumor growth in Solid Ehrlich Carcinoma (SEC)-bearing mice. Pim-1 kinase inhibitor 8 can be used for breast and liver cancer research .
    Pim-1 kinase inhibitor 8
  • HY-105529

    (+)-Indicine N-oxide; NSC 132319

    Microtubule/Tubulin Cancer
    Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research .
    Indicine N-oxide
  • HY-111786

    Toll-like Receptor (TLR) Cancer
    LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .
    LHC-165
  • HY-W001983

    Dihydropyrimidine Dehydrogenase (DPD) Cancer
    5-Iodouracil (Compound 4b) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor (IC50=0.22 μM). 5-Iodouracil is promising for research of DPD-overexpressing solid tumors like non-small cell lung cancer (NSCLC) .
    5-Iodouracil
  • HY-175322

    FAP Cancer
    FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors .
    FAPI-P8PN
  • HY-P991469

    MEDI-565

    Transmembrane Glycoprotein Cancer
    AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .
    AMG-211
  • HY-139453A

    DNA Alkylator/Crosslinker Cancer
    LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .
    LP-284
  • HY-16110

    UFT; BMS-200604

    Thymidylate Synthase Cancer
    Tegafur-Uracil (UFT; BMS-200604) is an effective oral chemotherapy drug based on fluoropyrimidine. Tegafur-Uracil inhibits thymidylate synthase. Tegafur-Uracil can be used in combination with leucovorin (LV) and polysaccharide K (PSK) for research on solid tumors .
    Tegafur-Uracil
  • HY-120409

    LPL Receptor Apoptosis Cancer
    AB1 is a highly selective S1P2 receptor antagonist (IC50=3.5 nM). AB1 inhibits sphingosine-1-phosphate (S1P) signaling, suppressing tumor cell migration, angiogenesis, and profibrotic mediator CTGF expression while inducing apoptosis. AB1 is promising for research of solid tumors .
    AB1
  • HY-178190

    Wee1 Cancer
    WEE1-IN-13 (Compound 10) is a highly selective WEE1 kinase inhibitor (IC50=0.7 nM). WEE1-IN-13 abrogates the G2/M checkpoint and induces tumor cell apoptosis. WEE1-IN-13 is promising for research of solid tumors (e.g., non-small cell lung cancer, ovarian cancer) .
    WEE1-IN-13
  • HY-137457A

    IDX-1197 hydrochloride

    PARP Cancer
    Venadaparib (IDX-1197) hydrochloride is a potent and selective PARP inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research .
    Venadaparib hydrochloride
  • HY-P99887

    JTX-4014

    PD-1/PD-L1 Cancer
    Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor .
    Pimivalimab
  • HY-157941A

    Drug Isomer Cancer
    (R,R)-ART0380 (Compound 38) is the enantiomer of ART0380 (HY-157941). ART0380 is a potent and selective ATR inhibitor. ART0380 can be used in studies of advanced or metastatic solid tumors .
    (R,R)-ART0380
  • HY-P991135

    RO-7502175; RG-6411

    CCR Cancer
    Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
    Enzelkitug
  • HY-114255

    alpha-TEA

    Apoptosis Cancer
    Alpha-tocopheryloxyacetic acid (alpha-TEA) is an inducer of cancer cell apoptosis pathway. Alpha-tocopheryloxyacetic acid is promising for research of solid and hematological malignancies .
    Alpha-tocopheryloxyacetic acid
  • HY-P991436

    BMS-986415

    Interleukin Related IFNAR Cancer
    DF6002 (BMS-986415) is a human monoclonal antibody (mAb) targeting IL-12. DF6002 increases IFN-γ levels. DF6002 can be used in solid tumors research .
    DF6002
  • HY-177913

    PDK-1 Cancer
    OSU-02067 is a selective 3-phosphoinositide-dependent protein kinase-1 (PDK-1) inhibitor (IC50=9 μM). OSU-02067 is promising for research of solid tumors (e.g., prostate, breast, colorectal cancers) .
    OSU-02067
  • HY-W016413

    Biochemical Assay Reagents Others
    4-(Hydroxymethyl)phenoxyacetic acid is an acid-labile resin linkage agent for use in solid phase peptide synthesis .
    4-(Hydroxymethyl)phenoxyacetic acid
  • HY-P991348

    PD-1/PD-L1 Cancer
    BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .
    BAT-1306
  • HY-P99619

    SCT-I10A

    PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
    Finotonlimab
  • HY-153243

    c-Fms Cancer
    IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a Ki value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research .
    IACS-9439
  • HY-19095

    Antifolate Cancer
    TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo .
    TNP-351
  • HY-177134

    VEGFR c-Met/HGFR Cancer
    Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
    Taligantinib
  • HY-124070

    MDM-2/p53 Cancer
    ISA 27 is a small-molecule MDM2-p53 protein-protein interaction inhibitor. ISA 27 inhibits MDM2-mediated p53 ubiquitination and degradation. ISA 27 is promising for research of p53-mutant solid tumors (e.g., thyroid, breast cancer) .
    ISA 27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: